These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 9529029)

  • 21. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis.
    de Vicente JC; Lequerica-Fernández P; Santamaría J; Fresno MF
    J Oral Pathol Med; 2007 Aug; 36(7):415-24. PubMed ID: 17617835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line.
    Lu KV; Jong KA; Rajasekaran AK; Cloughesy TF; Mischel PS
    Lab Invest; 2004 Jan; 84(1):8-20. PubMed ID: 14631378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PAF-induced furin and MT1-MMP expression is independent of MMP-2 activation in corneal myofibroblasts.
    Ottino P; He J; Axelrad TW; Bazan HE
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):487-96. PubMed ID: 15671273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
    Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
    Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.
    Vasala K; Turpeenniemi-Hujanen T
    Clin Biochem; 2007 Jun; 40(9-10):640-4. PubMed ID: 17374529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis.
    Hitchon CA; Danning CL; Illei GG; El-Gabalawy HS; Boumpas DT
    J Rheumatol; 2002 Jan; 29(1):107-17. PubMed ID: 11824946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
    Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.
    Afzal S; Lalani el-N ; Foulkes WD; Boyce B; Tickle S; Cardillo MR; Baker T; Pignatelli M; Stamp GW
    Lab Invest; 1996 Feb; 74(2):406-21. PubMed ID: 8780160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.
    Nakamura H; Ueno H; Yamashita K; Shimada T; Yamamoto E; Noguchi M; Fujimoto N; Sato H; Seiki M; Okada Y
    Cancer Res; 1999 Jan; 59(2):467-73. PubMed ID: 9927064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).
    Worley JR; Thompkins PB; Lee MH; Hutton M; Soloway P; Edwards DR; Murphy G; Knäuper V
    Biochem J; 2003 Jun; 372(Pt 3):799-809. PubMed ID: 12630911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.
    Ueno H; Nakamura H; Inoue M; Imai K; Noguchi M; Sato H; Seiki M; Okada Y
    Cancer Res; 1997 May; 57(10):2055-60. PubMed ID: 9158005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in bladder carcinoma.
    Xu K; Hou S; Du Z
    Chin Med J (Engl); 2002 May; 115(5):743-5. PubMed ID: 12133547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
    Miyata Y; Kanda S; Nomata K; Hayashida Y; Kanetake H
    Urology; 2004 Mar; 63(3):602-8. PubMed ID: 15028476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma.
    Gilles C; Polette M; Seiki M; Birembaut P; Thompson EW
    Lab Invest; 1997 May; 76(5):651-60. PubMed ID: 9166284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
    Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y
    Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.
    Jones JL; Glynn P; Walker RA
    J Pathol; 1999 Oct; 189(2):161-8. PubMed ID: 10547569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells.
    Wang C; Chen Z; Li Z; Cen J
    Leuk Res; 2010 Aug; 34(8):1083-90. PubMed ID: 20138666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane.
    Grigioni WF; D'Errico A; Fortunato C; Fiorentino M; Mancini AM; Stetler-Stevenson WG; Sobel ME; Liotta LA; Onisto M; Garbisa S
    Mod Pathol; 1994 Feb; 7(2):220-5. PubMed ID: 8008747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism.
    Monea S; Lehti K; Keski-Oja J; Mignatti P
    J Cell Physiol; 2002 Aug; 192(2):160-70. PubMed ID: 12115722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.